A new analysis of REDUCE-IT: benefits of omega-3s vs. harm from placebos
A secondary analysis of biomarker data from REDUCE-IT raises questions about the apparent benefits of EPA-derivative icosapent ethyl
#231 – AMA #41: Medicine 3.0, developments in the field of aging, healthy habits in times of stress, and more
“We have reached the limits of medicine 2.0 capacity, and if longevity is something we are aspiring for, we need a new strategy.” —Peter Attia
#230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more | Erin Michos, M.D.
“How we live the first half of our lives really influences our freedom for morbidity and mortality the second half of our lives.” —Erin Michos
Reassuring new data on statin-induced Lp(a) elevation
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?
Why a recent study hasn’t shaken my faith in statins
A rebuttal of Byrne et al.
Low LDL cholesterol and neural development
Why LDL-lowering treatments don’t pit head against heart
Does low cholesterol cause cognitive impairment? Part II
Safety of lipid-lowering therapy
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#116 – AMA with Dom D’Agostino, Ph.D., Part I of II: Ketogenic diet, exogenous ketones, and exercise
“If you restore insulin sensitivity, you’re better able to access and burn fat.” — Dom D’Agostino
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring